Sage Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sage Therapeutics, Inc.
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.
With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
- Medical Devices
Drug Discovery Tools
- Drug Discovery Tools